康泰生物
(300601)
| 流通市值：130.73亿 | | | 总市值：162.18亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 631,111,744.14 | 2,673,083,107.93 | 2,063,443,044.89 | 1,392,061,330.52 |
| 营业收入 | 631,111,744.14 | 2,673,083,107.93 | 2,063,443,044.89 | 1,392,061,330.52 |
| 二、营业总成本 | 599,367,752.11 | 2,504,875,738.79 | 1,925,316,368.3 | 1,293,245,266.49 |
| 营业成本 | 182,403,536.7 | 676,605,997.72 | 540,256,545.14 | 334,785,437.74 |
| 税金及附加 | 6,960,766.43 | 36,099,567.51 | 22,050,470.03 | 18,164,074.6 |
| 销售费用 | 231,130,893.21 | 894,386,572.83 | 691,523,243 | 470,244,772.23 |
| 管理费用 | 71,659,857.16 | 311,417,678.66 | 227,141,147.2 | 158,520,120.14 |
| 研发费用 | 84,280,329.82 | 543,416,537.82 | 420,069,200.59 | 296,924,139.62 |
| 财务费用 | 22,932,368.79 | 42,949,384.25 | 24,275,762.34 | 14,606,722.16 |
| 其中:利息费用 | 29,495,422.18 | 119,034,151.9 | 88,871,570.18 | 58,743,920.65 |
| 其中:利息收入 | 8,598,955.77 | 77,967,425.92 | 65,596,889.8 | 44,747,850.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,601,601.67 | 5,288,602.78 | 441,900 | 58,300 |
| 加:投资收益 | 124,339.27 | 1,509,002.51 | 134,484.89 | 99,250.45 |
| 资产处置收益 | 0 | -934,468.51 | -365,801.43 | -365,901.81 |
| 资产减值损失(新) | 6,002,037.86 | -133,831,177.41 | -128,795,085.37 | -93,665,145.75 |
| 信用减值损失(新) | -12,211,088.39 | -42,383,107.26 | -34,265,447.92 | -27,804,299.61 |
| 其他收益 | 7,375,474.04 | 40,213,083.87 | 30,616,044.12 | 24,587,238.97 |
| 四、营业利润 | 40,636,356.48 | 38,069,305.12 | 5,892,770.88 | 1,725,506.28 |
| 加:营业外收入 | 306,430.55 | 4,359,767.14 | 3,977,955.95 | 3,704,478.84 |
| 减:营业外支出 | 994,377.36 | -3,035,052.21 | 9,668,424.4 | 5,551,907.13 |
| 五、利润总额 | 39,948,409.67 | 45,464,124.47 | 202,302.43 | -121,922.01 |
| 减:所得税费用 | 6,348,338.57 | -24,809,822.75 | -48,980,055.15 | -37,722,832.42 |
| 六、净利润 | 33,600,071.1 | 70,273,947.22 | 49,182,357.58 | 37,600,910.41 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,600,071.1 | 70,273,947.22 | 49,182,357.58 | 37,600,910.41 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,339,022.65 | 70,330,463.43 | 49,157,674.08 | 37,532,743.65 |
| 少数股东损益 | 261,048.45 | -56,516.21 | 24,683.5 | 68,166.76 |
| 扣除非经常损益后的净利润 | 21,195,516.47 | 73,238,792.89 | 27,878,879.54 | 18,458,600.14 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.06 | 0.04 | 0.03 |
| (二)稀释每股收益 | 0.03 | 0.06 | 0.04 | 0.03 |
| 八、其他综合收益 | -35,940.55 | -115,810.65 | -93,372.99 | -95,966.13 |
| 归属于母公司股东的其他综合收益 | -35,940.55 | -115,810.65 | -93,372.99 | -95,966.13 |
| 九、综合收益总额 | 33,564,130.55 | 70,158,136.57 | 49,088,984.59 | 37,504,944.28 |
| 归属于母公司股东的综合收益总额 | 33,303,082.1 | 70,214,652.78 | 49,064,301.09 | 37,436,777.52 |
| 归属于少数股东的综合收益总额 | 261,048.45 | -56,516.21 | 24,683.5 | 68,166.76 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-28 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |